Pfenex (NYSEAMERICAN:PFNX) issued its quarterly earnings data on Thursday. The biotechnology company reported $0.09 EPS for the quarter, hitting analysts’ consensus estimates of $0.09, Fidelity Earnings reports. The company had revenue of $15.25 million for the quarter, compared to analyst estimates of $14.80 million.
Shares of PFNX traded up $0.51 during midday trading on Friday, reaching $10.68. The stock had a trading volume of 573,902 shares, compared to its average volume of 209,372. Pfenex has a one year low of $3.13 and a one year high of $11.39.
In other news, insider Patrick K. Lucy sold 6,000 shares of Pfenex stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $10.01, for a total value of $60,060.00.
Pfenex Inc, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study.
Further Reading: What is the CBOE Russell 2000® Volatility Index?
Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.